多発性硬化症と視神経脊髄炎

出版社： 中山書店
著者：
発行日： 2012-11-05
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784521734415
電子書籍版： 2012-11-05 （初版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

12,100 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

12,100 円(税込)

購入する

商品紹介

神経難病の代表的疾患である多発性硬化症や視神経脊髄炎は，近年，病態修飾療法が臨床応用されるようになったことで患者のQOLが大きく改善され，また，疾患特異的なバイオマーカーの発見も，神経内科領域で大きなトピックスとなっている。本書では，わが国で実地臨床に応用できる最新知見を網羅し，病態の把握から診断・治療・ケアまでを，豊富な図表・写真を用いてわかりやすく解説している。

目次

  • 多発性硬化症と視神経脊髄炎

    ―目次―

    1. 多発性硬化症の病態と死に断
    2. 多発性硬化症の治療とケア
    3．視神経脊髄炎の病態と治療
    Case Study

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 多発性硬化症の病態と診断

P.8 掲載の参考文献
1) Noonan CW, et al. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002 ; 58 : 136-138.
PubMed
2) Barnett MH, et al. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia : A 35-year study. J Neurol Sci 2003 ; 213 : 1-6.
 
3) Wallin MT, et al. Multiple sclerosis in US veterans of the Vietnam era and later military service : Race, sex, and geography. Ann Neurol 2004 ; 55 : 65-77.
PubMed
4) Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003 ; 2 : 117-127.
PubMed
5) Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis : A systematic review. Neurology 2008 ; 71 : 129-135.
PubMed
6) Houzen, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003 ; 211 : 49-53.
PubMed
7) Kuroiwa Y, et al. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 1975 ; 25 : 845-851.
PubMed
8) Shibasaki H, et al. Nationwide survey of multiple sclerosis in Japan : Reappraisal of clinical features. J Trop Geo Neurol 1992 ; 2 : 73-82.
 
9) Osoegawa M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : Nationwide survey results over 30 years. Mult Scler 2009 ; 15 : 159-173.
PubMed
10) Cocco E, et al. Anticipation of age at onset in multiple sclerosis : A Sardinian cohort study. Neurology 2004 ; 62 : 1794-1798.
PubMed
11) Ishizu T, et al. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neuol Sci 2009 ; 280 : 22-28.
 
12) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
13) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
14) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
15) Saida T, et al. Interferon beta-1b is effective in Japanese RRMS patients : A randomized, multicenter study. Neurology 2005 ; 64 : 621-630.
PubMed
16) Ochi H, et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci 2004 ; 222 : 65-73.
PubMed
17) Warabi Y, et al. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007 ; 252 : 57-61.
PubMed
18) Kappos L, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis : A 3-year follow-up analysis of the BENEFIT study. Lancet 2007 ; 370 : 389-397.
PubMed
19) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58 : 840-846.
 
20) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald Criteria. Ann Neurol 2011 ; 69 : 292-302.
 
21) Chong H, et al. Proposed modifications to the McDonald criteria for use in Asia. Mult Scler 2009 ; 15 : 887-888.
 
22) Lublin FD. Disease activity free status in MS. Multiple Sclerosis and Related Disorders 2011 ; 1 : 6-7.
 
P.17 掲載の参考文献
1) Noseworthy JH, et al. Multiple sclerosis. N Engl J Med 2000 ; 343 : 938-952.
PubMed
2) 吉良潤一. 日本人多発性硬化症の臨床研究における最近の進歩. 臨床神経学 2009 ; 49 : 549-559.
 
3) Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003 ; 2 : 117-127.
PubMed
4) Compston A, Confavreux C. The distribution of multiple sclerosis. In : Compston A, et al (editors), McAlpine's Multiple Sclerosis. 4th edition. London : Churchill Livingstone/Elsevier ; 2006, pp.71-111.
 
5) Sadovnick AD, et al. A population-based study of multiple sclerosis in twins : Update. Ann Neurol 1993 ; 33 : 281-285.
PubMed
6) Handel AE, et al. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010 ; 6 : 156-166.
PubMed
7) Sadovnick AD. The genetics of multiple sclerosis. Clin Neurol Neurosurg 2002 ; 104 : 199-202.
 
8) Poser CM. The epidemiology of multiple sclerosis : A general overview. Ann Neurol 1994 ; 36 (Supple 2) : S180-S193.
 
9) Peltonen L. Old suspects found guilty-The first genome profile of multiple sclerosis. N Engl J Med 2007 ; 357 : 927-929.
PubMed
10) Oksenberg JR, Baranzini SE. Multiple sclerosis genetics-Is the glass half full, or half empty? Nat Rev Neurol 2010 ; 6 : 429-437.
PubMed
11) Hafler DA, et al. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomwide study. N Engl J Med 2007 ; 357 : 851-862.
 
12) Gregory SG, et al. Interleukin 7 receptor α chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007 ; 39 : 1083-1091.
 
13) Lundmark F, et al. Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007 ; 39 : 1108-1113.
 
14) 吉良潤一. 多発性硬化症の臨床疫学-環境要因と遺伝要因. 日本臨牀 2003 ; 61 : 1300-1310.
Medical*Online
15) Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II : Noninfectious factors. Ann Neurol 2007 ; 61 : 504-513.
PubMed
16) Ascherio A, et al. Vitamin D and multiple sclerosis. Lancet Neurol 2010 ; 9 : 599-612.
PubMed
17) Handunnetthi L, et al. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010 ; 74 : 1905-1910.
PubMed
18) Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I : the role of infection. Ann Neurol 2007 ; 61 : 288-299.
PubMed
19) Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci 2000 ; 21 : 383-403.
PubMed
20) Rose JW. Multiple sclerosis : Evidence of maternal effects and an increasing incidence in women. Neurology 2009 ; 73 : 578-579.
 
21) Osoegawa M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : Nationwide survey results over 30 years. Mult Scler 2009 ; 15 : 159-173.
PubMed
22) Kotzamani D, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012 ; 78 : 1728-1735.
PubMed
23) 吉良潤一. 多発性硬化症-日本における最近の動向. 日本医事新報 2007 ; 4301 : 53-59.
 
24) 小副川学. 多発性硬化症の疫学-最近の全国臨床疫学調査からみえてくるもの. 医学のあゆみ 2006 ; 219 : 129-134.
Medical*Online
25) Houzen H, et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 2008 ; 14 : 887-892.
PubMed
P.27 掲載の参考文献
1) Kremenchutzky M, et al. The natural history of multiple sclerosis : A geographically based study 9 : observations on the progressive phase of the disease. Brain 2006 ; 129 : 584-594.
PubMed
2) Bronnum-Hansen H, et al. Survival and mortality rates among Danes with MS. Int MS J 2006 ; 13 : 66-71.
PubMed
3) Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007 ; 10 : 903-912.
PubMed
4) Confavreux C, et al. Relapses and progression of disability in multiple sclerosis. New Engl J Med 2000 ; 343 : 1430-1438.
PubMed
5) Pittock SJ, Rodriguez M. Benign multiple sclerosis : A distinct clinical entity with therapeutic implications. Curr Top Microbiol Immunol 2008 ; 318 : 1-17.
PubMed
6) Sayao AL, et al. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology 2007 ; 68 : 496-500.
PubMed
7) Ramsaransing GS, De Keyser J. Predictive value of clinical characteristics for "benign" multiple sclerosis. Eur J Neurol 2007 ; 14 : 885-889.
PubMed
8) Costelloe L, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Pscychiatr 2008 ; 79 : 1245-1248.
 
9) Glad SB, et al. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler 2009 ; 15 : 942-950.
PubMed
10) Skoog B, et al. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain 2012 ; 135 : 900-911.
PubMed
11) Cossburn M, et al. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler 2012 ; 18 : 45-54.
PubMed
12) Scalfari A, et al. Age and disability accumulation in multiple sclerosis. Neurology 2011 ; 77 : 1246-1252.
PubMed
13) Vukusic S, Confavreux C. Pregnancy and multiple sclerosis : The children of PRIMS. Clin Neurol Neurosurg 2006 ; 108 : 266-270.
PubMed
14) Bergamaschi R. Prognosis of multiple sclerosis : Clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006 ; 6 : 357-364.
PubMed
15) Degenhardt A, et al. Clinical prognostic factors in multiple sclerosis : A natural history review. Nat Rev Neurol 2009 ; 5 : 672-682.
PubMed
16) Brex PA, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002 ; 346 : 158-164.
PubMed
17) Boiko A, et al. Early onset multiple sclerosis : A longitudinal study. Neurology 2002 ; 59 : 1006-1010.
PubMed
18) Renoux C, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 ; 356 : 2603-2613.
PubMed
19) Osoegawa M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : Nationwide survey results over 30 years. Mult Scler 2009 ; 15 : 159-173.
PubMed
20) Ishizu T, et al. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neuol Sci 2009 ; 280 : 22-28.
 
21) Matsuoka T, et al. Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci 2008 ; 266 : 115-125.
PubMed
22) Matsuoka T, et al. Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. Mult Scler 2008 ; 14 : 1181-1190.
PubMed
P.36 掲載の参考文献
1) Lassmann H, et al. Immunopathology of multiple sclerosis : Report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998 ; 86 : 213-217.
 
2) Lucchinetti C. Multiple sclerosis pathology during early and late disease phases : Pathogenic and clinical relevance. In : Zhang J (editor). Immune Regulation and Immunotherapy in Autoimmune Disease. New York : Springer ; 2007, pp.214-264.
 
3) Prineas JW, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001 ; 50 : 646-657.
PubMed
4) Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 ; 128 : 2705-2712.
PubMed
5) Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions : Implications for the pathogenesis of demyelination. Ann Neurol 2000 ; 47 : 707-717.
PubMed
6) Ozawa K, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994 ; 117 : 1311-1322.
PubMed
7) Lucchinetti C, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999 ; 122 : 2279-2295.
PubMed
8) Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis : Pathology of the newly forming lesion. Ann Neurol 2004 ; 55 : 458-468.
PubMed
9) Henderson AP, et al. Multiple sclerosis : Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009 ; 66 : 739-753.
PubMed
10) Matsuoka T, et al. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 2010 ; 120 : 651-660.
PubMed
11) Matsuoka T, et al. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain pathol 2011 ; 21 : 516-532.
PubMed
12) Masaki K, et al. Extensive loss of connexins in Balo's disease : Evidence for an autoantibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte / myelin interaction. Acta Neuropathol 2012 ; 123 : 887-900.
PubMed
13) Ferguson B, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997 ; 120 : 393-399.
PubMed
14) Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 ; 338 : 278-285.
PubMed
15) Niki I, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011 ; 17 : 495-499.
 
16) Barkhof F, et al. Remyelinated lesions in multiple sclerosis : Magnetic resonance image appearance. Arch Neurol 2003 ; 60 : 1073-1081.
PubMed
17) Patrikios P, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006 ; 129 : 3165-3172.
 
18) Lucchinetti CF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011 ; 365 : 2188-2197.
PubMed
19) Howell OW, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011 ; 134 : 2755-2771.
PubMed
P.44 掲載の参考文献
1) Harrington LE, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005 ; 6 : 1123-1132.
 
2) Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005 ; 6 : 1133-1141.
 
3) Veldhoen M, et al. Transforming growth factor-beta'reprograms'the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008 ; 9 : 1341-1346.
PubMed
4) Jager A, et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009 ; 183 : 7169-7177.
PubMed
5) Panitch HS, Bever CT Jr. Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993 ; 46 : 155-164.
 
6) Tzartos JS, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008 ; 172 : 146-155.
PubMed
7) Brucklacher-Waldert V, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009 ; 132 : 3329-3341.
PubMed
8) Durelli L, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009 ; 65 : 499-509.
PubMed
9) Ramgolam VS, et al. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009 ; 183 : 5418-5427.
PubMed
10) Axtell RC, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010 ; 16 : 406-412.
PubMed
11) International Multiple Sclerosis Genetics Consortium ; Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 ; 476 : 214-219.
 
12) Bielekova B, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis : Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 ; 6 : 1167-1175.
PubMed
13) Fletcher JM, et al. CD39+ Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009 ; 183 : 7602-7610.
PubMed
14) Wynn DR, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE Study) : A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010 ; 9 : 381-390.
 
15) Annibali V, et al. CD161 (High) CD8+ T cells bear pathogenetic potential in multiple sclerosis. Brain 2011 ; 134 : 542-554.
PubMed
16) Kim HJ, et al. Inhibition of follicular T-helper cells by CD8 (+) regulatory T cells is essential for self tolerance. Nature 2010 ; 467 : 328-332.
PubMed
17) Bar-Or A, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010 ; 67 : 452-461.
PubMed
18) Masjuan J, et al. Clinically isolated syndromes : A new oligoclonal band test accurately predicts conversion to MS. Neurology 2006 ; 66 : 576-578.
 
19) Joseph FG, et al. CSF oligoclonal band status informs prognosis in multiple sclerosis : A case control study of 100 patients. J Neurol Neurosurg Psychiatr 2009 ; 80 : 292-296.
 
20) Ishizu T, et al. Intrathecal activation of the IL-17 / IL-8 axis in opticospinal multiple sclerosis. Brain 2005 ; 128 : 988-1002.
PubMed
21) Brettschneider J, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS ONE 2010 ; 5 : e11986.
PubMed
22) Teunissen CE, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009 ; 72 : 1322-1329.
PubMed
P.55 掲載の参考文献
1) Kasper DL, et al (editors). Harrison's Principles of Internal Medicine. 16th edition. New York : McGraw-Hill ; 2004.
 
2) Victor M, Ropper AH. Adams and Victor's Principles of Neurology. 7th edition. New York : McGraw-Hill ; 2001.
 
3) 高昌星. アトルバスタチンと多発性硬化症, 日本臨牀 2003 ; 61 : 1455-1460.
Medical*Online
4) Matthews WB, et al. McAlpine's Multiple Sclerosis. London : Churchill Livingstone ; 1999.
 
5) Hauser SL, et al (editors). Harrison's Neurology in Clinical Medicine. New York : McGraw-Hill ; 2006.
 
6) 高昌星. 免疫性神経疾患に対するアフェレシス. 日本アフェレシス学会雑誌 2001 ; 20 : 62-68.
 
7) Sekijima Y, et al. Serial magnetic resonance imaging (MRI) study of a patient with Balo's concentric sclerosis treated with immunoadsorption plasmapheresis. Mult Scler 1997 ; 2 : 291-294.
PubMed
8) Kurtzke JF. Rating neurologic impairment in multiple sclerosis : An expanded disability status scale (EDSS). Neurology 1983 ; 33 : 1444-1452.
PubMed
P.62 掲載の参考文献
1) Poser CM, et al. New diagnostic criteria for multiple sclerosis : Guidelines for research protocols. Ann Neurol 1983 ; 13 : 227-231.
PubMed
2) McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis : Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50 : 121-127.
PubMed
3) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 2011 ; 69 : 292-302.
 
4) Nakashima I, et al. Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1999 ; 67 : 153-157.
PubMed
5) Sajja BR, et al. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009 ; 19 : 45-58.
 
・ Kiferle L, et al. Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol 2011 ; 18 : 226-231.
PubMed
・ Sellner J, et al. The radiologically isolated syndrome : Take action when the unexpected is uncovered? J Neurol 2010 ; 257 : 1602-1611.
PubMed
・ Calabrese M, et al. Cortical lesions in multiple sclerosis. Nat Rev Neurol 2010 ; 6 : 438-444.
PubMed
P.69 掲載の参考文献
1) Gronseth GS, Ashman EJ. Practice parameter : The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 ; 54 : 1720-1725.
 
2) Lebrun C, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential : Follow-up of 70 patients. Arch Neurol 2009 ; 66 : 841-846.
PubMed
3) 飛松省三. 早わかり誘発電位 (2) -視覚誘発電位と聴覚脳幹誘発電位. 臨床脳波 2005 ; 47 : 638-648.
Medical*Online
4) Halliday AM, et al. Delayed visual evoked response in optic neuritis. Lancet 1972 ; 1 : 982-985.
PubMed
5) Holder GE, et al. International federation of clinical neurophysiology : Recommendations for visual system testing. Clin Neurophysiol 2010 ; 121 : 1393-1409.
PubMed
6) Tobimatsu S, Celesia GG. Studies of human visual pathophysiology with visual evoked potentials. Clin Neurophysiol 2006 ; 117 : 1414-1433.
PubMed
7) Watanabe A, et al. Multimodality-evoked potential study of anti-aquaporin-4 antibodypositive and -negative multiple sclerosis patients. J Neurol Sci 2009 ; 281 : 34-40.
PubMed
8) Cruccu G, et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 2008 ; 119 : 1705-1719.
PubMed
9) 飛松省三. 早わかり誘発電位 (3) -体性感覚誘発電位と運動誘発電位. 臨床脳波 2005 ; 47 : 717-726.
Medical*Online
10) 萩原綱一ほか. 多発性硬化症の電気生理診断学. 吉良潤一 (編), 多発性硬化症の診断と治療. 東京 : 新興医学出版社 ; 2008, pp.66-72.
 
11) Mayr N, et al. The sensitivity of transcranial cortical magnetic stimulation in detecting pyramidal tract lesions in clinically definite multiple sclerosis. Neurology 1991 ; 41 : 566-569.
PubMed
12) 黒川智美ほか. 電気生理学的診断法. 日本臨牀 2003 ; 61 : 1347-1354.
Medical*Online
・ 飛松省三. 早わかり誘発電位 (1) -誘発電位の基礎. 臨床脳波 2005 ; 47 : 573-583.
Medical*Online
P.84 掲載の参考文献
1) Miller DH, et al. Differential diagnosis of suspected multiple sclerosis : A consensus approach. Mult Scler 2008 ; 14 : 1157-1174.
PubMed
2) Schumacher GA, et al. Problems of experimental trials of therapy in multiple sclerosis : Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965 ; 122 : 552-568.
 
3) Poser CM, et al. New diagnostic criteria for multiple sclerosis : Guidelines for research protocols. Ann Neurol 1983 ; 13 : 227-231.
PubMed
4) McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis : Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50 : 121-127.
PubMed
5) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58 : 840-846.
 
6) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the "McDonald Criteria". Ann Neurol 2011 ; 69 : 292-302.
 
7) Swanton JK, et al. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J Neurol Neurosurg Psychiatry 2006 ; 77 : 1070-1072.
 
8) Montalban X, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010 ; 74 : 427-434.
PubMed
P.91 掲載の参考文献
1) Krupp LB, et al. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007 ; 68 : S7-S12.
 
2) Torisu H, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010 ; 32 : 454-462.
PubMed
3) 吉良潤一. 多発性硬化症-日本における最近の動向. 日本医事新報 2006 ; 4301 : 53-59.
Medical*Online
4) Banwell B, et al. Multiple sclerosis in children : Clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007 ; 6 : 887-902.
PubMed
5) Renoux C, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 ; 356 : 2603-2613.
PubMed
6) Chabas D, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010 ; 74 : 399-405.
PubMed
7) Tenembaum S, et al. Acute disseminated encephalomyelitis. Neurology 2007 ; 68 : S23-S36.
PubMed
8) Chabas D, et al. Vanishing MS T2-bright lesions before puberty : A distinct MRI phenotype? Neurology 2008 ; 71 : 1090-1093.
PubMed
9) Mikaeloff Y, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004 ; 127 : 1942-1947.
PubMed
10) Callen DJ, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009 ; 72 : 968-973.
PubMed
11) Ketelslegers IA, et al. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology 2010 ; 74 : 1412-1415.
PubMed
12) Verhey LH, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination : A prospective national cohort study. Lancet Neurol 2011 ; 10 : 1065-1073.
PubMed
13) 「多発性硬化症治療ガイドライン」作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
14) Yeh EA, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 2011 ; 68 : 437-444.
PubMed
15) Yeh EA, et al. Pediatric multiple sclerosis. Nat Rev Neurol 2009 ; 5 : 621-631.
PubMed
16) Mowry EM, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010 : 67 ; 618-624.
PubMed
17) Mikaeloff Y, et al. First episode of acute CNS inflammatory demyelination in childhood : Prognostic factors for multiple sclerosis and disability. J Pediatr 2004 ; 144 : 246-252.
PubMed
18) Mikaeloff Y, et al. Acute disseminated encephalomyelitis cohort study : Prognostic factors for relapse. Eur J Paediatr Neurol 2007 : 11 ; 90-95.
PubMed
19) Banwell B, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination : A prospective national cohort study. Lancet Neurol 2011 ; 10 : 436-445.
PubMed
P.98 掲載の参考文献
・ 吉良潤一. 多発性硬化症の診断と治療. 東京 : 新興医学出版社 ; 2008.
 
・ 多発性硬化症治療ガイドライン作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
・ 吉良潤一. 日本人多発性硬化症の臨床研究における最近の進歩. 臨床神経 2009 ; 49 : 549-559.
 
・ Hisanaga K, et al. Neuro-Sweet disease : Clinical manifestations and criteria for diagnosis. Neurology 2005 ; 64 : 1756-1761.
PubMed
P.103 掲載の参考文献
1) Balo J. Encephalitis periaxialis concentrica. Arch Neurol Psychiatry 1928 ; 19 : 242-264.
 
2) Marburg O. Die sogenannte 'akute multiple Sklerose' (Encephalomyelitis periaxialis scleroticans). Jb Neurol Psychiatr 1906 ; 27 : 213-312.
 
3) Hallervorden J, Spatz H. Uber die konzentrische Sklerose und die physikalischchemischen Faktoren bei der Ausbreitung von Entmarkungsprozessen. Arch Psychiat Nervenkr 1933 ; 98 : 641-701.
 
4) Stadelmann C, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005 ; 128 : 979-987.
 
5) Chen CJ, et al. Serial magnetic resonance imaging in patients with Balo's concentric sclerosis : Natural history of lesion development. Ann Neurol 1999 ; 46 : 651-656.
PubMed
6) Kastrup O, et al. Balo's concentric sclerosis. Evolution of active demyelination demonstrated by serial contrast-enhanced MRI. J Neurol 2002 ; 249 : 811-814.
PubMed
7) 田平武. 同心円硬化症 (Balo). 別冊日本臨牀 領域別症候群 1999 ; 27 : 423-426.
 
8) Wiendl H, et al. Diffusion abnormality in Balo's concentric sclerosis : Clues for the pathogenesis. Eur Neurol 2005 ; 53 : 42-44.
PubMed
9) Kavanagh EC, et al. Diffusion-weighted imaging findings in Balo concentric sclerosis. Br J Radiol 2006 ; 79 : e28-e31.
PubMed
10) Chen CJ. Serial proton magnetic resonance spectroscopy in lesions of Balo concentric sclerosis. J Comput Assist Tomogr 2001 ; 25 : 713-718.
PubMed
11) Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions : Implications for the pathogenesis of demyelination. Ann Neurol 2000 ; 47 : 707-717.
PubMed
12) Misu T, et al. Loss of aquaporin-4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 2007 ; 130 : 1224-1234.
PubMed
13) Bradl M, et al. Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66 : 630-643.
PubMed
14) Wang C, et al. Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler 2008 ; 14 : 418-424.
 
15) Wengert O, Siebert E. Images in clinical medicine. Balo's concentric sclerosis. N Engl J Med 2011 ; 365 : 742.
PubMed
16) Graber JJ, et al. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 2009 ; 66 : 274-275.
PubMed
17) Matsuoka T, et al. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 2010 ; 120 : 651-660.
PubMed
P.107 掲載の参考文献
1) Torisu H, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010 ; 32 : 454-462.
PubMed
2) Leake JA, et al. Acute disseminated encephalomyelitis in childhood : Epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004 ; 23 : 756-764.
PubMed
3) Fenichel GM. Neurological complications of immunization. Ann Neurol 1982 ; 12 : 119-128.
PubMed
4) Menge T, et al. Acute disseminated encephalomyelitis : An acute hit against the brain. Curr Opin Neurol 2007 ; 20 : 247-254.
PubMed
5) Brilot F, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009 ; 66 : 833-842.
PubMed
6) Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases : Implications for immunotherapy. Nat Rev Immunol 2002 ; 2 : 85-95.
PubMed
7) Wender M. Acute disseminated encephalomyelitis (ADEM). J Neuroimmunol 2011 ; 231 : 92-99.
 
8) Tenembaum S, et al. Acute disseminated encephalomyelitis : A long-term follow-up study of 84 pediatric patients. Neurology 2002 ; 59 : 1224-1231.
PubMed
9) Tenembaum S, et al. Acute disseminated encephalomyelitis. Neurology 2007 ; 68 : S23-36.
PubMed
10) Schwarz S, et al. Acute disseminated encephalomyelitis : A follow-up study of 40 adult patients. Neurology 2001 ; 56 : 1313-1318.
PubMed
11) Marchioni E, et al. Postinfectious inflammatory disorders : Subgroups based on prospective follow-up. Neurology 2005 ; 65 : 1057-1065.
PubMed
12) Lin CH, et al. Acute disseminated encephalomyelitis : A follow-up study in Taiwan. J Neurol Neurosurg Psychiatry 2007 ; 78 : 162-167.
PubMed
13) Dale RC, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis, and multiple sclerosis in children. Brain 2000 ; 123 : 2407-2422.
PubMed
14) Murthy SN, et al. Acute disseminated encephalomyelitis in children. Pediatrics 2002 ; 110 : e21.
PubMed
15) 鳥巣浩幸. 小児急性散在性脳脊髄炎の臨床像. 脳と発達 2011 ; 43 : S112.
Medical*Online
16) Mikaeloff Y, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004 ; 127 : 1942-1947.
PubMed
17) Alper G, et al. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow up : Comparison of presenting features. Dev Med Child Neurol 2009 ; 51 : 480-486.
PubMed
18) Anlar B, et al. Acute disseminated encephalomyelitis in children : Outcome and prognosis. Neuropediatrics 2003 ; 34 : 194-199.
PubMed
19) Jacobs RK, et al. Neuropsychological outcome after acute disseminated encephalomyelitis : Impact of age at illness onset. Pediatr Neurol 2004 ; 31 : 191-197.
PubMed
20) Mikaeloff Y, et al. Acute disseminated encephalomyelitis cohort study : Prognostic factors for relapse. Eur J Paediatr Neurol 2007 ; 11 : 90-95.
PubMed
P.114 掲載の参考文献
1) Kira J, et al. Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 1997 ; 148 : 199-203.
PubMed
2) Osoegawa M, et al. Myelitis with atopic diathesis : A nationwide survey of 79 cases in Japan. J Neurol Sci 2003 ; 209 : 5-11.
PubMed
3) Isobe N, et al. Neural damage associated with atopic diathesis : A nationwide survey in Japan. Neurology 2009 ; 73 : 790-797.
PubMed
4) Osoegawa M, et al. High incidence of subclinical peripheral neuropathy in myelitis with hyperIgEaemia and mite antigen-specific IgE (atopic myelitis) : An electrophysiolocal study. Intern Med 2002 ; 41 : 684-691.
 
5) Horiuchi I, et al. Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J Neurol Sci 2000 ; 172 : 17-24.
 
6) Tanaka M, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71 : 974-981.
PubMed
7) Kikuchi H, et al. Spinal cord lesions of myelitis with hyperIgEemia and mite antigen specific IgE (atopic myelitis) manifest eosinophic inflammation. J Neurol Sci 2000 ; 183 : 73-78.
 
8) Osoegawa M, et al. Eosinophilic myelitis associated with atopic diathesis : A combined neuroimaging and hitopathological study. Acta Neuropathol 2003 ; 105 : 289-295.
 
9) Isobe N, et al. First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci 2012 ; 316 : 30-35.
PubMed
10) Murai H, et al. Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci 2004 ; 227 : 39-47.
PubMed
P.118 掲載の参考文献
1) Di Trapani G, et al. Multiple sclerosis associated with peripheral demyelinating neuropathy. Clin Neuropathol 1996 ; 15 : 135-138.
PubMed
2) Rodriguez-Casero MV, et al. Childhood chronic inflammatory demyelinating polyneuropathy with central nervous system demyelination resembling multiple sclerosis. Neuromuscul Disord 2003 ; 13 : 158-161.
PubMed
3) Pender MP. The pathophysiology of acute experimental allergic encephalomyelitis induced by whole spinal cord in the Lewis rat. J Neurol Sci 1988 ; 84 : 209-222.
 
4) Falcone M, et al. Spreading of autoimmunity from central to peripheral myelin : Two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci 2006 ; 27 : 58-62.
PubMed
5) Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991 ; 41 : 617-618.
 
6) Misawa S, et al. Peripheral nerve demyelination in multiple sclerosis. Clin Neurophysiol 2008 ; 119 : 1829-1833.
PubMed
7) 小森哲夫ほか. 慢性炎症性脱髄性多発根神経炎における中枢神経障害-多発性硬化症との対比. 臨床神経学 1990 ; 30 : 939-943.
 
P.124 掲載の参考文献
1) Osoegawa M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese : Nationwide survey results over 30 years. Mult Scler 2009 ; 15 : 159-173.
PubMed
2) Marrosu MG, et al. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 1998 ; 7 : 1235-1237.
PubMed
3) Brynedal B, et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007 ; 2 : e664.
PubMed
4) Healy BC, et al. HLA B*44 : Protective effects in MS susceptibility and MRI outcome measures. Neurology 2010 ; 75 (7) : 634-640.
PubMed
5) International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007 ; 357 : 851-862.
PubMed
6) International Multiple Sclerosis Genetics Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 ; 476 (7359) : 214-219.
 
7) Kira J, et al. Western versus Asian types of multiple sclerosis : Immunogenetically and clinically distinct disorders. Ann Neurol 1996 ; 40 : 569-574.
PubMed
8) Yamasaki K, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis : Clinical, neuroimaging and immunogenetic studies. Brain 1999 ; 122 : 1689-1696.
PubMed
9) Kikuchi S, et al. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Neurology 2003 ; 60 : 647-651.
PubMed
10) Ono T, et al. Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Tissue Antigens 1998 ; 52 : 539-542.
 
11) Yoshimura S, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin-4 antibody status. J Neurol Neurosurg Psychiatry 2012 ; in press
 
12) McElroy JP, et al. SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun 2011 ; 12 (7) : 523-530.
PubMed
13) Fukazawa T, et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 1999 ; 166 (1) : 47-52.
PubMed
14) Niino M, et al. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol 2002 ; 127 (1-2) : 177-179.
 
15) Niino M, et al. Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neurol Sci 2000 ; 179 (S 1-2) : 70-75.
 
16) Fukazawa T, et al. CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol 2005 ; 159 (1-2) : 225-229.
 
17) Niino M, et al. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol 2003 ; 136 (1-2) : 125-129.
PubMed
18) Miyagishi R, et al. C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2003 ; 145 (1-2) : 135-138.
PubMed
19) Osoegawa M, et al. Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005 ; 161 (1-2) : 195-198.
PubMed
20) Fang L, et al. Interleukin-7 receptor alpha gene polymorphism influences multiple sclerosis risk in Asians. Neurology 2011 ; 76 (24) : 2125-2127.
PubMed
P.135 掲載の参考文献
1) Oksenberg JR, Baranzini SE. Multiple sclerosis genetics--is the glass half full, or half empty? Nat Rev Neurol 2010 ; 6 : 429-437.
PubMed
2) Lassmann H, et al. The immunopathology of multiple sclerosis : An overview. Brain Pathol 2007 ; 17 : 210-218.
PubMed
3) Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007 ; 6 : 202-210.
PubMed
4) Satoh J. Bioinformatics approach to identifying molecular biomarkers and networks in multiple sclerosis. Clin Exp Neuroimmunol 2010 ; 1 : 127-140.
 
5) 佐藤準一. アレイインフォマティクスの進展. YAKUGAKU ZASSHI 2008 ; 128 : 1537-1545.
Medical*Online
6) Huang da W, et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009 ; 4 : 44-57.
PubMed
7) The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007 ; 357 : 851-862.
PubMed
8) The International Multiple Sclerosis Genetics Consortium, the Wellcome Trust Case Control Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 ; 476 : 214-219.
 
9) Baranzini SE, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010 ; 464 : 1351-1356.
PubMed
10) Achiron A, et al. Blood transcriptional signatures of multiple sclerosis : Unique gene expression of disease activity. Ann Neurol 2004 ; 55 : 410-417.
PubMed
11) StUrzebecher S, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 2003 ; 126 : 1419-1429.
 
12) Satoh J, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005 ; 18 : 537-550.
PubMed
13) Satoh J, et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol 2006 ; 174 : 108-118.
PubMed
14) Comabella M, et al. A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain 2009 ; 132 : 3353-3365.
 
15) Satoh J, et al. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes : An implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurology 2006 ; 6 : 18.
 
16) Satoh J, et al. Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neurosci Lett 2007 ; 422 : 30-33.
 
17) Satoh J, et al. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-κB as a biomarker for relapse of multiple sclerosis. Dis Markers 2008 ; 25 : 27-35.
 
18) Lock C, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Med 2002 ; 8 : 500-508.
PubMed
19) Han MH, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008 ; 451 : 1076-1081.
PubMed
20) Satoh J, et al. Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 2009 ; 15 : 531-541.
PubMed
・ 藤渕航ほか (編). マイクロアレイデータ統計解析プロトコール. 東京 : 羊土社 ; 2008.
 
・ 小田吉哉ほか (編). 創薬・タンパク質研究のためのプロテオミクス解析. 東京 : 羊土社 ; 2010.
 
P.145 掲載の参考文献
1) Ramagopalan SV, et al. Multiple sclerosis : Risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010 ; 9 : 727-739.
PubMed
2) Handel AE, et al. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010 ; 6 : 156-166.
PubMed
3) Lauer K. Environmental risk factors in multiple sclerosis. Experi Rev Neurother 2010 ; 10 : 421-440.
 
4) Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008 ; 7 : 268-277.
PubMed
5) Kampman MT, et al. Outdoor activities and diet in chidhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007 ; 254 : 471-477.
 
6) Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006 ; 67 : 2085-2086.
PubMed
7) Levin LI, et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010 ; 67 : 824-830.
PubMed
8) Niino M. Vitamin D and its immunoregulatory role in multiple sclerosis. Drugs Today 2010 ; 46 : 279-290.
PubMed
9) Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for myltiple sclerosis? Brain 2010 ; 133 : 1869-1888.
 
10) Stein MS, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011 ; 77 : 1611-1618.
PubMed
P.149 掲載の参考文献
1) Gold R, et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models : 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006 ; 129 : 1953-1971.
PubMed
2) Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis : natalizumab. Nat Rev Drug Discov 2005 ; 4 : 510-518.
PubMed
3) Engelhardt B. T cell migration into the CNS during health and disease : Different molecular keys allow access to different CNS compartments. Clin Exp Neuroimmunol 2010 ; 1 : 79-93.
 
4) 能登大介, 山村隆. 免疫性神経疾患の免疫学. 内科 2010 ; 105 : 756-761.
 
5) Korn T et al. IL-17 and Th17 cells. Annual Rev Immunol 2009 ; 27 : 485-517.
 
6) Rothhammer V et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. JEM 2011 ; 208 : 2465-2476.
 
7) Glatigny S, et al. Cutting edge : Loss of a4 integrin expression differentially affects the homing of Th1 and Th17 cells. J Immunol 2011 ; 187 : 6176-6179.
 
8) Axtell RC, et al. T helper type 1 and 17 cells determine efficacy of interferon-b in multiple sclerosis and experimental encephalomyelitis. Nature Med 2010 ; 16 : 406-412.
 
9) Varrin-Doyer M, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012 ; 72 : 53-64.
PubMed
10) Kleiter I, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012 ; 69 : 239-245.
PubMed
11) Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009 ; 139 : 485-498.
PubMed
12) Yokote H, et al. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008 ; 173 : 1714-1723.
PubMed
P.155 掲載の参考文献
1) Li H, et al. Tumor necrosis factor-α promotes granulocyte-macrophage colonystimulating factor-stimulated microglia to differentiate into competent dendritic cell-like antigen-presenting cells. Clin Exp Neuroimmunol 2011 ; 2 : 1-11.
 
2) Sriran S. Role of glial cells in innate immunity and their role in CNS demyelination. J Neuroimmunol 2011 ; 239 : 13-20.
 
3) Vercellino M, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex : Correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007 ; 66 : 732-739.
PubMed
4) Takeuchi H, et al. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 2005 ; 280 : 10444-10454.
PubMed
5) Mizuno T, et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-γ receptor and AMPA GluR1 receptor. FASEB J 2008 ; 22 (6) : 1797-1806.
 
6) Zhou Y, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011 ; 186 (7) : 4415-4421.
PubMed
7) Chiang CS, et al. Macrophage / microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996 ; 97 : 1512-1524.
PubMed
8) Stumhofer JS, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006 ; 7 (9) : 937-945.
PubMed
9) Parratt JD, Prineas JW. Neuromyelitis optica : A demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 2010 ; 16 : 1156-1172.
PubMed
10) Yao SY, et al. In vitro and in vivo induction and activation of nNOS by ILS in oligodendrocytes. J Neuroimmunol 2010 ; 229 : 145-156.
 
11) Sloane JA, et al. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci U S A 2010 ; 107 : 11555-11560.
PubMed
・ Gandhi R, et al. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010 ; 221 : 7-14.
PubMed
・ 錫村明生. 神経細胞死におけるミクログリアの役割. 細胞工学 2011 ; 30 : 1042-1045.
Medical*Online
P.162 掲載の参考文献
1) Engelhardt B. T cell migration into the central nervous system during health and disease : Different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 2010 ; 1 : 79-93.
 
2) Zlokovic BV, et al. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 ; 57 : 171-201.
 
3) Shimizu F, et al. Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 2011 ; 226 : 225-266.
 
4) Prat A, et al. Glial cell influence on the human blood-brain barrier. Glia 2001 ; 36 : 145-155.
PubMed
5) Kermode AG, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990 ; 113 : 1477-1489.
PubMed
6) Engelhardt B, et al. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 1998 ; 102 : 2096-2105.
 
7) Engelhardt B, et al. Natalizumab : Targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008 ; 5 : 16-22.
PubMed
8) Argaw AT, et al. VEGF-mediated disruption of endothelial CLN-5 promotes bloodbrain barrier breakdown. Proc Natl Acad Sci U S A 2009 ; 106 : 1977-1982.
PubMed
9) Stamatovic SM, et al. Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells. J Biol Chem 2009 ; 284 : 19053-19066.
PubMed
10) Burnham JA, et al. The effect of high dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991 ; 41 : 1349-1354.
PubMed
11) Forster C, et al. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 2008 ; 586 : 1937-1949.
 
12) Kashiwamura Y, et al. Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res 2011 ; 36 : 849-855.
PubMed
13) Calabresi PA, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997 ; 41 : 669-674.
PubMed
14) Kraus J, et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004 ; 56 : 192-205.
PubMed
15) Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : Lessons from 28 cases. Lancet Neurol 2010 ; 9 : 438-446.
PubMed
16) Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med 2006 ; 354 : 924-933.
 
17) Sano Y, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 2010 ; 225 : 519-528.
 
18) Shimizu F, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 2012 ; 83 : 288-297.
PubMed
・ Alvarez JI, et al. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011 ; 1812 : 252-264.
PubMed
・ Kraus J, Oschmann P. The impact of interferon β treatment on the blood-brain barrier. Drug Discovery Today 2006 ; 11 : 755-762.
 
P.169 掲載の参考文献
1) 中原仁. 髄鞘の構造・機能・生化学. Clinical Neuroscience 2009 ; 27 : 1214-1217.
 
2) Levine JM, et al. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001 ; 24 : 39-47.
PubMed
3) Penderis J, et al. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 2003 ; 126 : 1382-1391.
 
4) Sowell ER, et al. Mapping cortical change across the human life span. Nat Neurosci 2003 ; 6 : 309-315.
PubMed
5) Bengtsson SL, et al. Extensive piano practicing has regionally specific effects on white matter development. Nat Neurosci 2005 ; 8 : 1148-1150.
PubMed
6) Pelvig DP, et al. Neocortical glial cell numbers in human brains. Neurobiol Aging 2008 ; 29 : 1754-1762.
PubMed
7) Barkhof F, et al. Remyelinated lesions in multiple sclerosis : Magnetic resonance image appearance. Arch Neurol 2003 ; 60 : 1073-1081.
PubMed
8) Patrikios P, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006 ; 129 : 3165-3172.
 
9) Goldschmidt T, et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009 ; 72 : 1914-1921.
PubMed
10) 中原仁ほか. 多発性硬化症における脱髄と髄鞘再生. 生体の科学 2006 ; 57 : 203-212.
 
11) Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998 ; 18 : 601-609.
PubMed
12) Charles P, et al. Re-expression of PSA-NCAM by demyelinated axons : An inhibitor of remyelination in multiple sclerosis? Brain 2002 ; 125 : 1972-1979.
PubMed
13) John GR, et al. Multiple sclerosis : Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002 ; 8 : 1115-1121.
PubMed
14) Back SA, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005 ; 11 : 966-972.
PubMed
15) Mi S, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005 ; 8 : 745-751.
PubMed
16) Satoh J, et al. TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2007 ; 33 : 99-107.
PubMed
17) Kotter MR, et al. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006 ; 26 : 328-332.
PubMed
18) Syed YA, et al. Inhibition of CNS remyelination by the presence of semaphorin 3A. J Neurosci 2011 ; 31 : 3719-3728.
PubMed
19) Trebst C, et al. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008 ; 14 : 728-733.
PubMed
20) Setzu A, et al. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 2006 ; 54 : 297-303.
PubMed
21) Hatch MN, et al. Endogenous remyelination is induced by transplant rejection in a viral model of multiple sclerosis. J Neuroimmunol 2009 ; 212 : 74-81.
 
22) Nakahara J, et al. Signaling via immunoglobulin Fc receptors induces oligodendrocyte precursor cell differentiation. Dev Cell 2003 ; 4 : 841-852.
PubMed
23) Nakahara J, et al. Fc receptor-positive cells in remyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 2006 ; 65 : 582-591.
PubMed
24) Nakahara J, et al. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest 2009 ; 119 : 169-181.
PubMed
25) Barnett MH, et al. Relapsing and remitting multiple sclerosis : Pathology of the newly forming lesion. Ann Neurol 2004 ; 55 : 458-468.
PubMed
・ Nave KA. Myelination and support of axonal integrity by glia. Nature 2010 ; 468 : 244-252.
PubMed
・ Kotter MR, et al. Enhancing remyelination in disease - can we wrap it up? Brain 2011 ; 134 : 1882-1900.
PubMed
・ Nakahara J, et al. Current concepts in multiple sclerosis : Autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 2012 ; 42 : 26-34.
PubMed

II. 多発性硬化症の治療とケア

P.176 掲載の参考文献
1) 日本神経学会ほか (監), 「多発性硬化症治療ガイドライン」作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
2) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58 : 840-846.
 
3) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
4) Misu T, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 2007 ; 130 : 1224-1234.
PubMed
5) Matsuoka T, et al. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 2011 ; 21 : 516-532.
PubMed
6) Hemmer B, Hartung H-P. Toward the development of rational therapies in multiple sclerosis : What is on the horizon? Ann Neurol 2007 ; 62 : 314-326.
PubMed
7) Shimizu Y, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008 ; 255 : 305-307.
PubMed
8) Kanzaki M, et al. Clinical features of opticospinal multiple sclerosis with anti-aquaporin 4 antibody. Eur Neurol 2008 ; 60 : 37-42.
PubMed
9) Shimizu J, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spetrum. Neurology 2010 ; 75 : 1423-1427.
 
10) Matsuoka T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130 : 1206-1223.
PubMed
11) Watanabe S, et al. Low dose corticosteroids reduce relapses in neuromyelitis optica : A retrospective analysis. Mult Scler 2007 ; 13 : 968-974.
PubMed
12) McDonald I, Compston A. The symptoms and signs of multiple sclerosis. In : Confavreux C, et a (l editors). McAlpine's Multiple Sclerosis, 4th edition. London : Churchill Livingstone ; 2006, pp.287-346.
 
13) Qiu W, et al. Spinal cord involvement of multiple sclerosis : A correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011 ; 300 : 114-119.
PubMed
14) 吉良潤一. 多発性硬化症-日本における最近の動向. 日本医事新報 2006 ; 4301 : 53-59.
Medical*Online
15) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 2011 ; 69 : 292-302.
 
P.182 掲載の参考文献
1) Pozzilli C, et al. Corticosteroids treatment. J Neurol Sci 2004 ; 223 : 47-51.
PubMed
2) Goodin DS, et al. Disease modifying therapies in multiple sclerosis : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 ; 58 : 169-178.
 
3) Milligan NM, et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis : 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987 ; 50 : 511-516.
PubMed
4) Miller DH, et al. High dose steroids in acute relapses of multiple sclerosis : MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992 ; 55 : 450-453.
PubMed
5) Oliveri RL, et al. Randomized trial comparing two different high doses of methylprednisolone in MS : A clinical and MRI study. Neurology 1998 ; 50 : 1833-1836.
 
6) Beck RW, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992 ; 326 : 581-588.
PubMed
7) Beck RW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993 ; 329 : 1764-1769.
PubMed
8) Wakakura M, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J Ophthalmol 1999 ; 43 : 133-138.
PubMed
9) 田中正美, 松井大. NMO の治療の実際と問題点. Brain Medical 2010 ; 22 : 61-66.
 
10) Pozzilli C, et al. Monthly corticosteroids decrease neutralizing antibodies to IFN-β -1b : A randomized trial in multiple sclerosis. J Neurol 2002 ; 249 : 50-56.
 
11) Goodkin DE, et al. A phase II study of IV methylprednisolone in secondaryprogressive multiple sclerosis. Neurology 1998 ; 51 : 239-245.
PubMed
12) Glass-Marmor L, et al. Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry 2007 ; 78 : 886-888.
PubMed
13) Zivadinov R, et al. Effects of IV methylprednisolone on brain atrophy in relapsingremitting MS. Neurology 2001 ; 57 : 1239-1247.
PubMed
・ 日本神経学会ほか (監), 「多発性硬化症治療ガイドライン」作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
P.192 掲載の参考文献
1) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
2) 野村恭一. 多発性硬化症. 日本アフェレシス学会雑誌 2004 ; 23 (3) : 227-233.
 
3) Goto H, et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 2001 ; 5 : 494-496.
PubMed
4) De Luca G, et al. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1999 ; 95 : 190-194.
PubMed
5) 阿岸鉄三. 血漿浄化療法概論 (特徴, 適応, 最近の進歩). 日本臨牀 2004 ; 62 (Suppl 5) : 307-312.
 
6) 野村恭一ほか. 免疫吸着 (TR-350) 療法は自己抗体のIgGサブクラスにより除去能が異なる. 厚生労働科学研究 難治性疾患克服研究事業, 免疫性神経疾患に関する調査研究班, 平成20年度報告書. 2009, pp.52-55.
 
7) Weiner HL, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989 ; 39 (9) : 1143-1149.
PubMed
8) Weinshenker BG, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999 ; 46 (6) : 878-886.
PubMed
9) Schmitt E, et al. Immunoadsorption with phenylalanine-immobilized polyvinyl alcohol versus plasma exchange - A controlled pilot study in multiple sclerosis. Ther Plasmapheresis 1993 ; 12 : 239-242.
 
10) Canadian Cooperative MS Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991 ; 337 (8739) : 441-446.
 
11) 平山浩一, 小山哲夫. 血漿交換療法に伴う副作用. 日本臨牀 2004 ; 62 (Suppl 5) : 319-327.
 
12) 塩川優一. 日本におけるプラスマフェレシス (この10年の歩み). 日本アフェレシス学会 (編), プラスマフェレシスマニュアル '93. 東京 : 中外医学社 ; 1993, pp.1-12.
 
13) Watanabe S, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007 ; 13 (1) : 128-132.
PubMed
14) 野村恭一ほか. 厚生労働科学研究費補助金 難治性疾患克服研究事業, 免疫性神経疾患に関する調査研究班, 平成19年度報告書. 2008, pp.82-84.
 
15) Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007 ; 6 : 805-815.
PubMed
・ 日本神経学会ほか (監). 「多発性硬化症治療ガイドライン作成委員会」 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
・ 野村恭一. 神経疾患. 日本アフェレシス学会 (編), アフェレシスマニュアル, 改訂第3版. 東京 : 秀潤社 ; 2010, pp.336-362.
 
P.203 掲載の参考文献
1) The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993 ; 43 (4) : 655-661.
 
2) The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39 (3) : 285-294.
 
3) PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352 (9139) : 1498-1504.
 
4) Saida T, et al. Interferon beta-1b is effective in Japanese RRMS patients : A randomized, multicenter study. Neurology 2005 ; 64 (4) : 621-630.
PubMed
5) 隅野留理子. 多発性硬化症治療薬インターフェロンベータ-1a製剤 (アボネックス筋注用シリンジ30μg) の薬理学的特性および臨床試験成績. 日薬理誌 2007 ; 129 (3) : 209-217.
 
6) European Study Group on interferon beta-1b in secondary progressive MS. Placebocontrolled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 ; 352 (9139) : 1491-1497.
 
7) Panitch H, et al ; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS : Results from a 3-year controlled study. Neurology 2004 ; 63 (10) : 1788-1795.
 
8) Cohen JA, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001 ; 58 (6) : 961-967.
 
9) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS : Clinical results. Neurology 2001 ; 56 (11) : 1496-1504.
 
10) Leary SM, et al. Interferon beta-1a in primary progressive MS : An exploratory, randomized, controlled trial. Neurology 2003 ; 60 : 44-51.
PubMed
11) Montalban X. Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult Scler 2004 ; 10 (Suppl 1) : S62-64.
 
12) Kappos L, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67 (7) : 1242-1249.
 
13) Jacobs LD, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343 (13) : 898-904.
 
14) Comi G, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis : A randomised study. Early Treatment of Multiple Sclerosis Study Group. Lancet 2001 ; 357 (9268) : 1576-1582.
 
15) Trojano M, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007 ; 61 (4) : 300-306.
PubMed
16) Durelli L, et al ; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis : Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 ; 359 (9316) : 1453-1460.
 
17) Panitch H, et al ; EVIDENCE Study Group. EVidence of Interferon Dose-response : Europian North American Compartative Efficacy ; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS : The EVIDENCE Trial. Neurology 2002 ; 59 (10) : 1496-1506.
 
18) Rio J, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 ; 59 (2) : 344-352.
PubMed
19) Cohen BA, et al. Identifying and treating patients with suboptimal responses. Neurology 2004 ; 63 (12 Suppl 6) : S33-40.
 
20) Rio J, et al. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009 ; 5 (10) : 553-560.
PubMed
21) Ebers GC, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010 ; 81 (8) : 907-912.
 
22) Goodin DS, et al. Establishing long-term efficacy in chronic disease : Use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2011 ; 6 (11) : e22444.
PubMed
23) Goodin DS, et al. Survival in MS : A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012 ; 78 (17) : 1315-1322.
 
24) Kinkel RP, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes : A 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012 ; 69 (2) : 183-190.
PubMed
25) Sorensen PS, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis : Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 ; 12 (11) : 817-827.
PubMed
26) 藤原一男ほか. 日本人MSにおけるIFNβ中和抗体の陽性頻度の検討と臨床的意義の解析. 厚生労働科学研究費補助金 難治性疾患克服研究事業, 免疫性神経疾患に関する調査研究班, 平成23年度総括・分担研究報告書, 2011.
 
P.215 掲載の参考文献
1) Matloubian M, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004 ; 427 : 355-360.
PubMed
2) Chun J, et al. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010 ; 33 : 91-101.
PubMed
3) Mehling M, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008 ; 71 : 1261-1267.
 
4) Kowarik MC, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011 ; 76 : 1214-1221.
PubMed
5) Chiba K, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998 ; 160 : 5037-5044.
 
6) Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptor. Pharmacol Ther 2005 ; 108 : 308-319.
PubMed
7) Miron VE, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008 ; 63 : 61-71.
PubMed
8) Harada J, et al. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004 ; 88 : 1026-1039.
PubMed
9) Cohen JA, et al. Mechanism of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011 ; 69 : 759-777.
PubMed
10) Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 387-401.
 
11) Cohen JA, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 402-415.
 
12) Saida T, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012 ; 18 : 1269-1277.
PubMed
13) Kira J, et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis : Results of a 12-month, phase 2 extension study. Mult Scler 2011 ; 17 (Supple 10) : S193.
 
14) Min JH, et al. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012 ; 18 : 113-115.
 
15) Matsushita T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibodynegative opticospinal multiple sclerosis in Japanese. Mult Scler 2009 ; 15 : 834-847.
PubMed
16) Espinosa PS, et al. Delayed fingolimod-associated asystole. Mult Scler 2011 ; 17 : 1387-1389.
PubMed
17) 多発性硬化症治療剤「ジレニア(R) カプセル 0.5 mg」の添付文書の「警告」および「重要な基本的注意」の改訂について. ノバルティスファーマ株式会社. 2012年3月.
 
18) 多発性硬化症治療剤「イムセラ(R) カプセル 0.5 mg」添付文書の「警告」および「重要な基本的注意」改訂に関するお知らせ. 田辺三菱製薬株式会社. 2012年3月.
 
19) Fingolimod investigator letter PML case 12. April 2012 final. Fingolimod investigator letter based on information to Novartis on April 12 2012.
 
20) Allende ML, et al. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002 ; 1582 : 222-227.
PubMed
21) ノバルティスファーマ (株) ジレニア(R) 適正使用ガイド改訂第2版. 監修 藤原一男 : 2012年3月作成.
 
22) イムセラカプセル 0.5 mg, ジレニアカプセル 0.5 mg 承認審査情報. http://www.info.pmda.go.jp/shinyaku/P201100158/index.html
 
P.223 掲載の参考文献
1) 小森美華ほか. 多発性硬化症におけるミトキサントロン治療. BRAIN and NERVE 2009 ; 61 : 575-580.
 
2) Le Page E, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis : treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008 ; 79 : 52-56.
 
3) 「多発性硬化症治療ガイドライン」作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
4) Ellis R, et al. Therapy-related acute leukaemia with Mitoxantrone : What is the risk and can we minimise it? Mult Scler 2009 ; 15 : 505-508.
PubMed
5) Patti F, et al. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis 2011 ; 2011 : 961702.
PubMed
6) Elkhalifa AS, Weiner H. Cyclophosphamide treatment of MS : Current therapeutic approaches and treatment regimens. Int MS J 2010 ; 17 : 12-18.
PubMed
7) Casetta I, et al. Azathioprine for multiple sclerosis. J Neurol Neurosurg Psychiatry 2009 ; 80 : 131-132.
PubMed
8) Invernizzi P, et al. Azathioprine in multiple sclerosis. Mini Rev Med Chem 2008 ; 8 : 919-926.
PubMed
9) Cohen JA, et al. Results of the Avonex Combination Trial (ACT) in relapsingremitting MS. Neurology 2009 ; 72 : 535-541.
PubMed
・ Neurology 2004 ; 63 (12 Supple 6) : S1-S46.
 
・ Marriott JJ, et al. Evidence report : The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010 ; 74 : 1463-1470.
 
・ Awad A, et al. Cyclophosphamide in multiple sclerosis : Scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord 2009 ; 2 : 50-61.
PubMed
P.228 掲載の参考文献
1) 岡田和将ほか. 免疫グロブリン大量静注療法の位置づけ. 吉良潤一 (編), 多発性硬化症の治療と診断. 東京 : 新興医学出版社 ; 2008, pp.188-197.
 
2) Jorgensen SH, et al. Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res 2005 ; 27 : 591-597.
PubMed
3) Achiron A, et al. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun 2000 ; 15 : 323-330.
PubMed
4) Sorensen PS, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004 ; 63 : 2028-2033.
PubMed
5) Elovaara I, et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol 2011 ; 34 : 84-89.
PubMed
6) Feasby T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007 ; 21 (2 Suppl 1) : S57-107.
 
7) Fazekas F, et al. Intravenous immunoglobulin in relapsing- remitting multiple sclerosis : A dose-finding trial. Neurology 2008 ; 71 : 265-271.
PubMed
8) Achiron A, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis : A randomized, double-blind, placebo-controlled trial. Arch Neurol 2004 ; 61 : 1515-1520.
PubMed
9) Hellwig K, et al. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord 2009 ; 2 : 7-11.
PubMed
10) Pohlau D, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis : A randomized placebo controlled mutlicentre study. Mult Scler 2007 ; 13 : 1107-1117.
 
11) Katz U, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007 ; 6 : 257-259.
PubMed
12) Stangel M, Gold R. Intravenous immunoglobulins in MS. Int MS J 2005 ; 12 : 5-10, 4.
PubMed
13) Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004 ; 31 : 265-267.
PubMed
14) Okada K, et al. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007 ; 46 : 1671-1672.
PubMed
15) Lewanska M, et al. No difference in efficacy of two different doses of intravenous immunoglobulins in MS : Clinical and MRI assessment. Eur J Neurol 2002 ; 9 : 565-572.
PubMed
・ 吉良潤一 (編). 多発性硬化症の診断と治療. 東京 : 新興医学出版社, 2007.
 
・ Soelberg Sorensen P. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegener Dis 2008 ; 5 : 8-15.
PubMed
・ Baerenwaldt A, et al. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010 ; 6 : 425-434.
PubMed
P.233 掲載の参考文献
1) Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 899-910.
PubMed
2) Rudick RA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 911-923.
PubMed
3) Miller DH, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007 ; 68 : 1390-1401.
 
4) Hutchinson M, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis : subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009 ; 256 : 405-415.
PubMed
5) Kappos L, et al. Natalizumab treatment for multiple sclerosis : updated recommendations for patient selection and monitoring. Lancet Neurol 2011 ; 10 : 745-758.
PubMed
6) Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : lessons from 28 cases. Lancet Neurol 2010 ; 9 : 438-446.
PubMed
7) Wenning W, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009 ; 361 : 1075-1080.
PubMed
8) 新野正明, 佐々木秀直. 多発性硬化症の免疫学・免疫遺伝学. 吉良潤一 (編), 多発性硬化症の診断と治療. 東京 : 新興医学出版社 ; 2008, pp.25-29.
 
9) Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011 ; 258 : 1920-1928.
PubMed
P.239 掲載の参考文献
1) Hill-Cawthorne GA, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2011 ; 83 : 298-304.
PubMed
2) Jones JL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010 ; 133 : 2232-2247.
PubMed
3) Moreau T, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994 ; 344 : 298-301.
PubMed
4) Coles AJ, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999 ; 46 : 296-304.
PubMed
5) Coles AJ, et al. The window of therapeutic opportunity in multiple sclerosis : Evidence from monoclonal antibody therapy. J Neurol 2006 ; 253 : 98-108.
PubMed
6) The CAMMS223 Trial Investigators, Coles AJ, et al. Alemzutumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008 ; 359 : 1786-1801.
PubMed
7) Coles AJ, et al. Alemtuzumab versus interferon beta-1a in early relapsing -remitting multiple sclerosis : Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011 ; 10 : 338-348.
PubMed
8) Hirst CL, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008 ; 255 : 231-238.
PubMed
9) Cossburn M, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011 ; 77 : 573-579.
 
10) Jones JL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009 ; 119 : 2052-2061.
PubMed
P.245 掲載の参考文献
1) Bielekova B, Becker BL. Monoclonal antibodies in MS : Mechanisms of action. Neurology 2010 ; 74 (Suppl 1) : S31-S40.
 
2) Weiner GJ. Rituximab : Mechanism of action. Semin Hematol 2010 ; 47 : 115-123.
PubMed
3) Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 ; 358 : 676-688.
PubMed
4) Bar-Or A, et al. Rituximab in relapsing-remitting multiple sclerosis : A 72-week, openlabel, phase I trial. Ann Neurol 2008 ; 63 : 395-400.
PubMed
5) Naismith RT, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis : A 52-week phase II trial. Neurology 2010 ; 74 : 1860-1867.
 
6) Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006 ; 180 : 63-70.
 
7) Pellkofer HL, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011 ; 76 : 1310-1315.
PubMed
8) Kim SH, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011 ; 68 : 1412-1420.
PubMed
9) Monson NL, et al. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 2011 ; 6 : e17103.
 
10) Cree BA, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005 ; 64 : 1270-1272.
PubMed
11) Jacob A, et al. Treatment of neuromyelitis optica with rituximab : Retrospective analysis of 25 patients. Arch Neurol 2008 ; 65 : 1443-1448.
PubMed
12) Hawker K, et al. Rituximab in patients with primary progressive multiple sclerosis : Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009 ; 66 : 460-471.
PubMed
13) Bedi GS, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011 ; 17 : 1225-1230.
PubMed
14) Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients : A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 ; 113 : 4834-4840.
PubMed
・ Berer K, et al. B cells in spontaneous autoimmune diseases of the central nervous system. Mol Immunol 2011 ; 48 : 1332-1337.
PubMed
P.254 掲載の参考文献
1) Sigal DS, et al. Beyond hairy cell : The activity of cladribine in other hematologic malignancies. Blood 2010 ; 116 (16) : 2884-2896.
PubMed
2) Sipe JC, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994 ; 344 : 9-13.
PubMed
3) Beutler E, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996 ; 93 : 1716-1720.
PubMed
4) Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 ; 362 : 416-426.
PubMed
5) Giovannoni G, et al. Sustained disease-activity-free status in patients with relapsingremitting multiple sclerosis treated with cladribine tablets in the CLARITY study : A post-hoc and subgroup analysis. Lancet Neurol 2011 ; 10 : 329-337.
PubMed
6) Bielekova B, Becker BL. Monoclonal antibodies in MS : Mechanisms of action. Neurology 2010 ; 74 (Suppl 1) : S31-S40.
 
7) Oh U, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009 ; 66 (4) : 471-479.
PubMed
8) Bielekova B, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009 ; 66 (4) : 483-489.
 
9) Bielekova B, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004 ; 101 (23) : 8705-8708.
PubMed
10) Rose JW, el al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004 ; 56 : 864-867.
 
11) Wynn D, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study) : A phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010 ; 9 : 381-390.
PubMed
12) Rojas MA, et al. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2009 ; 2 (5) : 291-297.
PubMed
13) Bielekova B, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011 ; 77 : 1877-1886.
PubMed
14) http://www.expert-reviews.com/
 
15) Kappos L, et al. Efficacy and safety of oral fumarate in patients with relapsingremitting multiple sclerosis : A multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008 ; 372 : 1463-1472.
PubMed
16) http://www.biogenidec.com/
 
17) Gold R, et al. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2011 ; 124 : 75-84.
PubMed
18) Tallantyre E, et al. Spotlight on teriflunomide. Int MS J 2008 ; 15 : 62-68.
PubMed
19) O'Connor P, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Eng J Med 2011 ; 365 : 1293-1303.
 
P.262 掲載の参考文献
1) Rekand T. Clinical assessment and management of spasticity : A review. Acta Neurol Scand Suppl 2010 ; 190 : 62-66.
PubMed
2) Truini A, et al. Treating pain in multiple sclerosis. Expert Opin Pharmacother 2011 ; 12 : 2355-2368.
PubMed
3) Bosma R, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction : A meta-analysis. Acta Neurol Scand 2005 ; 112 ; 1-5.
PubMed
4) Hosseini H, et al. Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis. Neurosurg 2011 [Epub ahead of print]
 
5) Tomassini V, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis : Results of a pilot, randomized doubleblind. crossover trial. J Neurol Sci 2004 ; 218 : 103-108.
PubMed
6) Lovera JF, et al. Memantine for cognitive impairment in multiple sclerosis : A randomized placebo-controlled trial. Mult Scler 2010 ; 16 : 715-723.
PubMed
7) Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Am J Manag Care 2011 ; 17 (Suppl 5) : S154-S160.
 
・ de Sa JC, et al. Symptomatic therapy in multiple sclerosis : A review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011 ; 4 : 139-168.
PubMed
・ Frohman TC, et al. Symptomatic therapy in multiple sclerosis. Ther Adv Neurol Disord 2011 ; 4 : 83-98.
PubMed
P.271 掲載の参考文献
1) De Keyser J. Autoimmunity in multiple sclerosis. Neurology 1988 ; 38 : 371-374.
PubMed
2) Seyfert S, et al. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand 1990 ; 81 : 37-42.
PubMed
3) 小副川学. MRI画像所見からみた日本人MS病像の解析-2004年MS全国臨床疫学調査. 神経免疫学 2006 ; 14 : 151-155.
 
4) 吉良潤一. 多発性硬化症-日本における最近の動向. 日本医事新報 2006 ; 4301 : 53-59.
Medical*Online
5) Koutouzov S, et al. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 2006 ; 5 : 554-562.
PubMed
6) Nordmark G, et al. Mechanisms of Disease : Primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006 ; 2 : 262-269.
PubMed
7) 「多発性硬化症治療ガイドライン」作成委員会 (編). 膠原病合併 (Sjogren症候群など). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010, pp.110-125.
 
8) Polman CH, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005 ; 64 : 996-1000.
 
9) Caraccio N, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy : Predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005 ; 90 : 4133-4137.
PubMed
10) Monzani F, et al. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004 ; 3 : 199-210.
PubMed
11) Alexander EL, et al. Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 1986 ; 104 : 323-330.
PubMed
12) 「多発性硬化症治療ガイドライン」作成委員会 (編). 視神経脊髄炎患者・抗アクアポリン 4 抗体陽性患者. 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010. pp.92-103.
 
13) Wingerchuk DM, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53 : 1107-1114.
PubMed
14) 吉良潤一ほか. 多発性硬化症 (MS) 2004年全国臨床疫学調査結果第3報-合併症からみた日本人MSの病像. 厚生労働科学研究費補助金 難治性疾患克服研究事業, 免疫性神経疾患に関する調査研究 (主任研究者 吉良潤一), 平成17年度 総括・分担研究報告書. 2005, pp.151-152.
 
15) Ciccarelli O, et al. Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis. Mult Scler 2000 ; 6 : 137-139.
 
16) Hirohata M, et al. Reversible cortical lesions in primary Sjogren's syndrome presenting with meningoencephalitis as an initial manifestation. J Neurol Sci 2005 ; 232 : 111-113.
PubMed
17) Williams CS, et al. Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001 ; 58 : 815-819.
PubMed
18) Kovacs B, et al. Transverse myelopathy in systemic lupus erythematosus : An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000 ; 59 : 120-124.
PubMed
P.278 掲載の参考文献
1) Poser S, Poser W. Multiple sclerosis and gestation. Neurology 1983 ; 33 : 1422-1427.
PubMed
2) Confavreux C, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998 ; 339 : 285-291.
 
3) Vukusic S, et al. Pregnancy and multiple sclerosis (the PRIMS study) : Clinical predictors of post-partum relapse. Brain 2004 ; 127 : 1353-1360.
PubMed
4) Langer-Gould A, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009 ; 66 : 958-963.
PubMed
5) Airas L, et al. Breast-feeding, postpartum and pregnancy disease activity in multiple sclerosis. Neurology 2010 : 75 ; 474-476.
PubMed
6) Portaccio E, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011 ; 77 : 145-150.
 
7) Damek DM, Shuster EA. Pregnancy and multiple sclerosis. Mayo Clin Proc 1997 ; 72 : 977-989.
PubMed
8) Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000 ; 160 : 610-619.
PubMed
9) 小川法良, 菅井進. 膠原病の治療薬剤-副腎皮質ステロイド剤. 臨と研 1999 ; 76 : 1682-1686.
Medical*Online
10) 田中憲一ほか (編). スキルアップのための妊婦への服薬指導. 東京 : 南山堂 ; 2003.
 
11) 杉江和馬ほか. 妊娠を契機に発症した重症筋無力症の1症例. 神経内科 2001 ; 54 : 363-366.
 
12) 大橋高志ほか. 視神経脊髄炎 (NMO) における免疫吸着療法の検討. 東女医大誌 2008 ; 78 (臨時増刊) : E94-E98.
 
13) Walther EU, Hohlfeld R. Multiple sclerosis : Side effects of interferon beta therapy and their management. Neurology 1999 ; 53 : 1622-1627.
PubMed
14) Panitch H, et al. Interferon β-1b in secondary progressive MS : Results from a 3 year controlled study. Neurology 2004 ; 63 : 1788-1795.
 
15) Sandberg-Wollheim M, et al. Pregnancy outcomes during treatment with interferon β-1a in patients with multiple sclerosis. Neurology 2005 ; 65 : 802-806.
 
16) Boskovic R, et al. The reproductive effects of beta interferon therapy in pregnancy : A longitudinal cohort. Neurology 2005 ; 65 : 807-811.
PubMed
17) De las Heras V, et al. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy : A descriptive study in the Spanish population. Mult Scler 2007 ; 13 : 981-984.
PubMed
18) Patti F, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 2008 ; 255 : 1250-1253.
PubMed
19) バイエル薬品 (株). ベタフェロン(R) 皮下注, 添付文書. 2008年8月.
 
20) バイオジェン・アイディック・ジャパン (株). アボネックス(R) 筋注用シリンジ, 添付文書. 2009年2月.
 
21) ノバルティスファーマ (株). ジレニア(R) 適正使用ガイド. 藤原一男 (監). 2011年11月.
 
22) ノバルティスファーマ (株). ジレニア(R) カプセル 0.5 mg, 添付文書. 2011年9月.
 
23) Ferrero S, et al. Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. Expert Rev Neurother 2006 ; 6 : 1823-1831.
 
24) Bourre B, et al. Neuromyelitis optica and Pregnancy. Neurology 2012 ; 78 : 875-879.
PubMed
25) Kim W, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 2012 ; 78 : 1264-1267.
PubMed
・ Offner H, Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2006 ; 1089 : 343-372.
PubMed
・ Saito S, et al. Th1 / Th2 / Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010 ; 63 : 601-610.
PubMed
P.287 掲載の参考文献
1) Saida T, et al ; Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients : A randomized, multicenter study. Neurology 2005 ; 64 : 621-630.
 
2) Goodin DS, et al. Survival in MS : A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012 ; 78 : 1315-1322.
 
3) Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol 2007 ; 79 : 423-447.
PubMed
・ 水野美邦 (編). 神経内科ハンドブック-鑑別診断と治療, 第4版. 東京 : 医学書院 ; 2010.
 
・ 「多発性硬化症治療ガイドライン」作成委員会 (編). 多発性硬化症治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
P.291 掲載の参考文献
1) Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis : The impact of fatigue and depression. J Neurol Sci 2002 ; 205 : 51-58.
PubMed
2) Amato M P, et al. Quality of life in multiple sclerosis : The impact of depression, fatigue and disability. Mult Scler 2001 ; 7 (5) : 340-344.
PubMed
3) Benedict R H, et al. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler 2003 ; 9 : 393-396.
PubMed
4) Benito-Leon J, et al. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur Neurol 2002 ; 9 (5) : 497-502.
PubMed
5) Baumstarck-Barrau K, et al. Cognitive function and quality of life in multiple sclerosis patients : A cross-sectional study. BMC Neurol 2011 ; 11 : 17.
PubMed
6) Cutajar R, et al. Cognitive function and quality of life in multiple sclerosis patients. J Neurovirol 2000 ; 6 (Suppl 2) : S186-190.
 
7) Schurch B, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007 ; 88 : 646-652.
PubMed
8) Jongen PJ, et al. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol 2010 ; 257 (4) : 584-589.
PubMed
9) Putzki N, et al. Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009 ; 16 (6) : 713-720.
PubMed
10) Simone I L, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 2006 ; 4 : 96.
PubMed
11) Patti F, et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler 2007 ; 13 (6) : 783-791.
PubMed
12) Wundes A. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ 2010 ; 13 (4) : 626-632.
 
13) Ishizu T, et al. Heterogeneity and continuum of multiple sclerosis of the forth nationwide survey. J Neurol Sci 2009 ; 280 (1-2) : 22-28.
 
14) Kikuchi H, et al. Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 2011 ; 20 (1) : 119-131.
PubMed
15) 菊地誠志, 菊地ひろみ. 多発性硬化症. 北村聖 (編), 臨床病態学1巻. 東京 : ヌーヴェルヒロカワ ; 2007, pp.139-145.
 
16) 菊地誠志ほか. 多発性硬化症患者へのインフォームドコンセントとQOL. 吉良潤一 (編), 多発性硬化症の診断と治療. 東京 : 新興医学出版社 ; 2008, pp.133-143.
 
P.302 掲載の参考文献
1) Phillips CJ, Humphreys I. Assessing cost-effectiveness in the management of multiple sclerosis. Clinicoecon Outcomes Res 2009 ; 1 : 61-78.
PubMed
2) Goldberg LD, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009 ; 15 (7) : 543-555.
PubMed
・ 荻野美恵子. 厚生労働科学研究費補助金 難治性疾患克服研究事業, 難治性疾患の医療費構造に関する研究. 平成20年度総括・分担研究報告書. 2009年3月. 平成21年度総括・分担研究報告書. 2010年3月, および別冊. 平成22年度総括・分担研究報告書. 2011年3月, および別冊. 平成20～22年度総合研究報告書. 2011年3月.
 

III. 視神経脊髄炎の病態と治療

P.313 掲載の参考文献
1) 藤原一男ほか. Neuromyelitis optica (Devic病) -原典とその今日的意義. 神経内科 2002 ; 56 : 306-311.
 
2) Mandler RN, et al. Devic's neuromyelitis optica : A clinicopathological study of 8 patients. Ann Neurol 1993 ; 34 : 162-168.
PubMed
3) Wingerchuk DM, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53 : 1107-1114.
PubMed
4) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
5) Miller DH, et al. Differential diagnosis of suspected multiple sclerosis : A consensus approach. Mult Scler 2008 ; 14 : 1157-1174.
PubMed
6) Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007 ; 6 : 805-815.
PubMed
7) Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 2011 ; 306 : 183-187.
PubMed
P.321 掲載の参考文献
1) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
2) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
3) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
4) Papadopoulos MC, et al. Molecular mechanisms of brain tumor edema. Neuroscience 2004 ; 129 : 1011-1020.
PubMed
5) Friedman B, et al. Acute vascular distruption and aquaporin 4 loss after stroke. Stroke 2009 ; 40 : 2182-2190.
 
6) Tani T, et al. Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J Neuroimmunol 2009 ; 211 : 110-113.
PubMed
7) Lihua Li, et al. Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout mice BMC. Neuroscience 2009 ; 10 : 94.
PubMed
8) Lihua Li, et al. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J 2011 ; 25 : 1556-1566.
PubMed
9) Hinson SR, et al. Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012 ; 109 : 1245-1250.
PubMed
10) Tanaka K, et al. Anti-aquaporin 4 antibody in Japanese multiple sclerosis with long spinal cord lesions. Mult Scler 2007 ; 13 : 850-855.
PubMed
11) Matsuoka T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130 : 1206-1223.
PubMed
12) Takahashi T, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO : A study on antibody titre. Brain 2007 ; 130 : 1235-1243.
 
13) Paul F, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007 ; 4 : e133.
PubMed
14) Waters P, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008 ; 65 : 913-919.
PubMed
15) Waters PJ, et al. Serologic diagnosis of NMO : A multicenter comparison of aquaporin-4-IgG assays. Neurol 2012 ; 78 : 665-671.
 
16) Isobe N, et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler 2012 ; 1352458512443917.
PubMed
17) Nagaishi A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort : Comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011 ; 82 : 1360-1364.
 
18) Yanagawa K, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009 ; 73 : 1628-1637.
PubMed
19) Jung JS, et al. Molecular characterization of an aquaporin cDNA from brain : Candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A 1994 ; 91 : 13052-13056.
PubMed
20) Kinoshita M, et al. Neuromyelitis optica : Passive transfer to rat by human immunoglobulin. Biochem Biophys Res Commun 2009 ; 386 : 623-627.
PubMed
21) Bennett JL, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009 ; 66 : 617-629.
PubMed
22) Bradl M, et al. Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66 : 630-643.
PubMed
23) Saadoun S, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010 ; 133 : 349-361.
PubMed
・ Waters PJ, et al. Serologic diagnosis of NMO : A multicenter comparison of aquaporin-4-IgG assays. Neurol 2012 ; 78 : 665-671.
 
・ Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica : Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010 ; 6 : 383-392.
PubMed
P.330 掲載の参考文献
1) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
2) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 2011 ; 69 : 292-302.
 
3) 中野志仁ほか. 抗アクアポリン4抗体陽性の高齢発症反復性脊髄炎の1例. Brain and Nerve 2009 ; 61 : 201-204.
 
4) 吉村怜, 吉良潤一. 多発性硬化症の疫学-全国臨床疫学調査からみえてきたもの. 医学のあゆみ 2011 ; 237 : 284-290.
Medical*Online
5) Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010 ; 12 : 244-255.
PubMed
6) Cornelio DB, et al. Devic's neuromyelitis optica and pregnancy : Distinction from multiple sclerosis is essential. Arch Gynecol Obstet 2009 ; 280 : 475-477.
PubMed
7) 中尾雄三ほか. 抗アクアポリン4抗体陽性視神経炎の臨床的特徴. 神経眼科 2008 ; 25 : 327-342.
Medical*Online
8) Nagelhus EA, et al. Aquaporin-4 water channel protein in the rat retina and optic nerve : Poralized expression in Muller cells and fibrous astrocytes. J Neurosci 1998 ; 18 : 2506-2519.
 
9) Venero JL, et al. Detailed localization of aquaporin-4 messenger RNA in the CNS : Preferential expression in periventricular organs. Neuroscience 1999 ; 94 : 239-250.
PubMed
10) Nakao Y, et al. Differential diagnosis of enlarged optic nerve and/or sheath on MR imaging. Shimizu K (editor). Current Aspects in Ophthalmology : Proceedings of the Xiii Congress of the Asia-Pacific Academy of Opthalmology. Kyoto : Excerpta Medica ; 1992, pp.1671-1675.
 
11) 宮本勝一. 視神経脊髄炎 (NMO) の病態. 山村隆 (編), 多発性硬化症 (MS) 診療のすべて. 東京 : 診断と治療社 ; 2012, pp.164-169.
 
12) 清水優子. NMOの頭部MRIからみた臨床像の特徴. Brain and Nerve 2010 ; 62 : 933-943.
 
13) Misu T, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005 ; 65 : 1479-1482.
PubMed
14) Nakamura M, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009 ; 15 : 695-700.
PubMed
15) Ito S, et al. "Cloud-like enhancement"is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009 ; 66 : 425-428.
PubMed
16) Takahashi T, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO : A study on antibody titre. Brain 2007 ; 130 : 1235-1243.
 
17) Takano R, et al. Astrocytic damage is far more severe than demyelination in NMO : A clinical CSF biomarker study. Neurology 2010 ; 75 : 208-216.
PubMed
18) Kira J. Neuromyelitis optica and opticospinal multiple sclerosis : Mechanisms and pathogenesis. Pathophysiology 2011 ; 18 : 69-79.
PubMed
19) Uzawa A, et al. Cytokine and chemokine profiles in neuromyelitis optica : Significance of interleukin-6. Mult Scler 2010 ; 16 : 1443-1452.
PubMed
20) Uzawa A, et al. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 2012 ; 83 : 339-340.
PubMed
・ Sellner J, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010 ; 17 : 1019-1032.
PubMed
P.337 掲載の参考文献
1) Wingerchuk DM, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53 : 1107-1114.
PubMed
2) Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002 ; 125 : 1450-1461.
PubMed
3) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
4) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
5) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
6) Miller DH, et al. Differential diagnosis of suspected multiple sclerosis : A consensus approach. Mult Scler 2008 ; 14 : 1157-1174.
PubMed
7) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the McDonald criteria. Ann Neurol 2011 ; 69 : 292-302.
 
8) Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007 ; 6 : 805-815.
PubMed
9) Jacob A, et al. Neuromyelitis optica : Changing concepts. J Neuroimmunol 2007 ; 187 : 126-138.
PubMed
10) Yanagawa K, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009 ; 73 : 1628-1637.
PubMed
11) Sellner J, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010 ; 17 : 1019-1032.
PubMed
12) Matiello M, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008 ; 70 : 2197-2200.
PubMed
13) Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012 ; 18 : 5-10.
PubMed
14) Popescu BF, et al. Neuromyelitis optica unique area postrema lesions : Nausea, vomiting, and pathogenic implications. Neurology 2011 ; 76 : 1229-1237.
PubMed
15) Kanbayashi T, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis : New neurochemical and immunological implications. Arch Neurol 2009 ; 66 : 1563-1566.
PubMed
16) Pittock SJ, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006 ; 63 : 390-396.
PubMed
P.342 掲載の参考文献
1) Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004 ; 63 : 2363-2370.
PubMed
2) Ishizu T, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005 ; 128 : 98-1002.
 
3) Tanaka M, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71 : 974-981.
PubMed
4) Yanagawa K, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009 ; 73 : 1628-1637.
PubMed
5) Uzawa A, et al. Cytokine and chemokine profiles in neuromyelitis optica : Significance of interleukin-6. Mult Scler 2010 ; 16 : 1443-1452.
PubMed
6) Icoz S, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010 ; 120 : 71-75.
PubMed
7) Chihara N, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011 ; 108 : 3701-3706.
PubMed
8) Robertson NP, et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996 ; 119 (Pt 2) : 449-455.
 
9) Oksenberg JR, Baranzini SE. Multiple sclerosis genetics : Is the glass half full, or half empty? Nat Rev Neurol 2010 ; 6 : 429-437.
PubMed
10) Braley T, et al. Neuromyelitis optica in a mother and daughter. Arch Neurol 2007 ; 64 : 1189-1192.
 
11) Matiello M, et al. Familial neuromyelitis optica. Neurology 2010 ; 75 : 310-315.
PubMed
12) Cabrera-Gomez JA, et al. Neuromyelitis optica and multiple sclerosis in sisters. Mult Scler 2009 ; 15 : 269-271.
PubMed
13) Yamasaki K, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis : Clinical, neuroimaging and immunogenetic studies. Brain 1999 ; 122 (Pt 9) : 1689-1696.
 
14) Matsushita T, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009 ; 73 : 171-176.
PubMed
15) Wang H, et al. HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese. J Neuroimmunol 2011 ; 233 : 181-184.
 
16) Kim HJ, et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis 2010 ; 37 : 349-355.
PubMed
17) McElroy JP, et al. SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun 2011 ; 12 : 523-530.
PubMed
18) Narikawa K, et al. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004 ; 149 : 182-186.
PubMed
19) Uzawa A, et al. Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurol 2010 ; 10 : 113.
PubMed
P.349 掲載の参考文献
1) Wingerchuk DM, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999 ; 53 (5) : 1107-1114.
PubMed
2) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 (4) : 473-477.
 
3) Wingerchuk DM, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007 ; 6 (9) : 805-815.
PubMed
4) Mandler RN, et al. Devic's neuromyelitis optica : A clinicopathological study of 8 patients. Ann Neurol 1993 ; 34 (2) : 162-168.
PubMed
5) Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002 ; 125 (Pt 7) : 1450-1461.
 
6) Misu T, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica : A case report. Tohoku J Exp Med 2006 ; 209 (3) : 269-275.
PubMed
7) Misu T, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 2007 ; 130 (Pt 5) : 1224-1234.
 
8) Hinson SR, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007 ; 69 (24) : 2221-2231.
PubMed
9) Vincent T, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008 ; 181 (8) : 5730-5737.
PubMed
10) Kinoshita M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009 ; 20 (5) : 508-512.
PubMed
11) Bradl M, et al. Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66 (5) : 630-643.
PubMed
12) Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions : Implications for the pathogenesis of demyelination. Ann Neurol 2000 ; 47 (6) : 707-717.
PubMed
13) Keegan M, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005 ; 366 (9485) : 579-582.
PubMed
14) Barnett MH, et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009 ; 65 (1) : 32-46.
PubMed
15) Breij EC, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008 ; 63 (1) : 16-25.
PubMed
16) Lassmann H, et al. Heterogeneity of multiple sclerosis pathogenesis : Implications for diagnosis and therapy. Trends Mol Med 2001 ; 7 (3) : 115-121.
PubMed
17) Matsuoka T, et al. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 2010 ; 120 (5) : 651-660.
PubMed
18) Sharma R, et al. Inflammation induced by innate immunity in the nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010 ; 120 (2) : 223-236.
PubMed
P.356 掲載の参考文献
1) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
2) Kinoshita M, et al. Neuromyelitis optica : Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009 ; 386 : 623-627.
PubMed
3) Misu T, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 2007 ; 130 : 1224-1234.
PubMed
4) Kinoshita M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009 ; 20 : 508-512.
PubMed
5) Nishiyama S, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009 ; 72 : 1960-1961.
 
6) Matsushita T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibodynegative opticospinal multiple sclerosis in Japanese. Mult Scler 2009 ; 15 : 834-847.
PubMed
7) Kinoshita M, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010 ; 394 : 205-210.
PubMed
8) Raghavendra V, et al. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004 ; 20 : 467-473.
PubMed
9) Saadoun S, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010 ; 133 : 349-361.
PubMed
10) Rus H, et al. The complement system in central nervous system diseases. Autoimmunity 2006 ; 39 : 395-402.
PubMed
11) Bradl M, et al. Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66 : 630-643.
PubMed
12) Hinson SR, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008 ; 205 : 2473-2481.
PubMed
13) Vincent T, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008 ; 181 : 5730-5737.
PubMed
14) McKeon A, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008 ; 71 : 93-100.
PubMed
15) Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009 ; 9 : 393-407.
PubMed
16) Matsuoka T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130 : 1206-1223.
PubMed
P.364 掲載の参考文献
1) Nakamura M, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010 ; 248 : 1777-1785.
PubMed
2) Keegan M, et al. Plasma exchange for severe attacks of CNS demyelination : Predictors of response. Neurology 2002 ; 58 : 143-146.
PubMed
3) Watanabe S, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007 ; 13 : 128-132.
PubMed
4) Ohashi T, et al. Immunoadsorption plasma pheresis for the treatment of neuromyelitis optica spectrum disorder. Mult Scler 2008 ; 14 : S170.
 
5) Weinshenker BG, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006 ; 59 : 566-569.
PubMed
6) Sellner J, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010 ; 17 : 1019-1032.
PubMed
7) Watanabe S, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica : A retrospective analysis. Mult Scler 2007 ; 13 : 968-974.
PubMed
8) Mandler RN, et al. Devic's neuromyelitis optica : A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998 ; 51 : 1219-1220.
PubMed
9) Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008 ; 10 : 55-66.
PubMed
10) Jacob A, et al. Treatment of neuromyelitis optica with mycophenolate mofetil : Retrospective analysis of 24 patients. Arch Neurol 2009 ; 66 : 1128-1133.
PubMed
11) Kim SH, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011 ; 68 : 1412-1420.
PubMed
12) Okada K, et al. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007 ; 46 : 1671-1672.
PubMed
13) Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009 ; 13 : 505-508.
PubMed
14) Bergamaschi R, et al. A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 2003 ; 250 : 359-361.
PubMed
15) Tradtrantip L, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012 ; 71 : 314-322.
PubMed
P.368 掲載の参考文献
1) Shibasaki H, Kuroiwa Y. EEG abnormality in optic spinal form of multiple sclerosis. Eur Neurol 1974 ; 11 : 218-226.
PubMed
2) Fukazawa T, et al. Antineutrophil cytoplasmic antibodies and the optic-spinal form of multiple sclerosis in Japan. J Neurol Neurosurg Psychiatry 1996 ; 61 : 203-204.
PubMed
3) Fukazawa T, et al. Anti-nuclear antibodies and the optic-spinal form of multiple sclerosis. J Neurol 1997 ; 244 : 483-488.
PubMed
4) Sakuma R, et al. Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies. J Neurol 1999 ; 246 : 449-453.
PubMed
5) Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica : Distinction from multiple sclerosis. Lancet 2004 ; 364 : 2106-2112.
PubMed
6) Lennon VA, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 ; 202 : 473-477.
 
7) Takahashi T, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006 ; 210 : 307-313.
PubMed
8) Chihara N, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011 ; 108 : 3701-3706.
PubMed
9) Komori M, et al. Proteomic pattern analysis discriminates among multiple sclerosisrelated disorders. Ann Neurol 2012 ; 71 : 614-623.
PubMed
10) Kim W, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010 ; 16 : 1229-1236.
PubMed
11) Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica : Current status of the assays. Int MS J 2008 ; 15 : 99-105.
PubMed
12) Watanabe S, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica : A retrospective analysis. Mult Scler 2007 ; 13 : 968-974.
PubMed
13) Watanabe S, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007 ; 13 : 128-132.
PubMed
P.380 掲載の参考文献
1) Kira J. Neuromyelitis optica and opticospinal multiple sclerosis : Mechanisms and pathogenesis. Pathophysiology 2011 ; 18 : 69-79.
PubMed
2) Roemer SF, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007 ; 130 : 1194-1205.
PubMed
3) Misu T, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica : Distinction from multiple sclerosis. Brain 2007 ; 130 : 1224-1234.
PubMed
4) Matsuoka T, et al. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 2011 ; 21 : 516-532.
PubMed
5) Kobayashi Z, et al. Intractable hiccup caused by medulla oblongata lesions : A study of an autopsy patient with possible neuromyelitis optica. J Neurol Sci 2009 ; 285 : 241-245.
PubMed
6) Matsuoka T, et al. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 2010 ; 120 : 651-660.
PubMed
7) Kira J. Astrocytopathy in Balo's disease. Mult Scler 2011 ; 17 : 771-779.
PubMed
8) Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis : Astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 2011 ; 311 : 69-77.
PubMed
9) Manley GT, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000 ; 6 : 159-163.
PubMed
10) Papadopoulos MC, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 2004 ; 18 : 1291-1293.
PubMed
11) Li L, et al. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J 2011 ; 25 : 1556-1566.
PubMed
12) Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions : Implications for the pathogenesis of demyelination. Ann Neurol 2000 ; 47 : 707-717.
PubMed
13) Masaki K, et al. Extensive loss of connexins in Balo's disease : Evidence for an autoantibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol 2012 ; 123 : 887-900.
PubMed
14) Bradl M, et al. Neuromyelitis optica : Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009 ; 66 : 630-643.
PubMed
15) Kinoshita M, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010 ; 394 : 205-210.
PubMed
16) Saadoun S, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010 ; 133 : 349-361.
PubMed
17) Ratelade J, et al. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem 2011 ; 286 : 45156-45164.
PubMed
18) Hinson SR, et al. Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012 ; 109 : 1245-1250.
PubMed
19) Isobe N, et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler 2012 Apr 23. [Epub ahead of print].
 
20) Fazio R, et al. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 2009 ; 15 : 1153-1163.
PubMed
21) Collongues N, et al. Neuromyelitis optica in France : A multicenter study of 125 patients. Neurology 2010 ; 74 : 736-742.
 
22) Wingerchuk DM, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 ; 66 : 1485-1489.
PubMed
23) Matsushita T, et al. Reappraisal of brain MRI features in multiple sclerosis and neuromyelitis optica patients according to anti-aquaporin-4 antibody status. J Neurol Sci 2010 ; 291 : 37-43.
PubMed
24) Pittock SJ, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006 ; 63 : 390-396.
PubMed
25) Matsuoka T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130 : 1206-1223.
PubMed
26) Matsushita T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler 2009 ; 15 : 834-847.
PubMed
27) Siritho S, et al. AQP4 antibody-positive Thai cases : Clinical features and diagnostic problems. Neurology 2011 ; 77 : 827-834.
PubMed
28) Jarius S, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008 ; 131 : 3072-3080.
 
29) Nishiyama S, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009 ; 72 : 1960-1961.
 
30) Pittock SJ, et al. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008 ; 65 : 629-632.
 
31) Ishizu T, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005 ; 128 : 988-1002.
PubMed
32) Tanaka M, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71 : 974-981.
PubMed
33) Yonekawa T, et al. T cell reactivities to myelin protein-derived peptides in neuromyelitis optica patients with anti-aquaporin-4 antibody. Neurology Asia 2011 ; 16 : 139-142.
 
34) Mathey EK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007 ; 204 : 2363-2372.
PubMed
35) Srivastava R, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012 ; 367 : 115-123.
PubMed
36) Isobe N, et al. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult Scler 2010 ; 16 : 147-155.
PubMed
37) Cotrina ML, et al. Brain connexins in demyelinating diseases : Therapeutic potential of glial targets. Brain Res 2012 Jul 10. [Epub ahead of print]
 

Case Study

P.386 掲載の参考文献
1) Tanaka M, et al. Interferon-beta (1b) treatment in neuromyelitis optica. Eur Neurol 2009 ; 62 (3) : 167-170.
PubMed
2) Uzawa A, et al. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010 ; 17 (5) : 672-676.
PubMed
3) Warabi Y, et al. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007 ; 252 (1) : 57-61.
PubMed
4) Shimizu Y, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 2008 ; 255 (2) : 305-307.
PubMed
5) Shimizu J, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010 ; 75 (16) : 1423-1427.
 
6) Shimizu Y, et al. Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med 2011 ; 223 (3) : 211-214
 
P.393 掲載の参考文献
1) Lucchinetti CF, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008 ; 131 : 1759-1775.
PubMed
2) Kiriyama T, et al. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 2011 ; 21 : e69-e77.
 
3) Kim DS, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma : Added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 2009 ; 251 : 467-475.
PubMed
4) Malhotra HS, et al. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009 ; 15 : 193-203.
PubMed
5) Cianfoni A, et al. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am Neuroradiol 2007 ; 28 : 272-277.
PubMed
6) Masdeu JC, et al. Open-ring imaging sign : Highly specific for atypical brain demyelination. Neurology 2000 ; 54 : 1427-1433.
PubMed
7) Cha S, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001 ; 22 : 1109-1116.
PubMed
8) Poser S, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992 ; 86 : 579-585.
PubMed
9) Dastgir J, et al. Acute tumefactive demylinating lesions in a pediatric with known diagnosis of multiple sclerosis : Review of literature and treatment proposal. J Child Neurol 2009 ; 24 : 431-437.
 
10) 荒川博之, ほか. 腫瘍様変化を呈する多発性硬化症 (MS), 急性散在性脳脊髄炎 (ADEM) の臨床的検討. 神経免疫学 2008 ; 16 : 93.
 
11) McAdam LC, et al. Pediatric tumefactive demyelination : Case series and review of literature. Pediatr Neurol 2002 ; 26 : 18-25.
PubMed
12) Haupts MR, et al. Fulminant tumefactive multiple sclerosis : Therapeutic implications of histopathology. J Neurol 2008 ; 255 : 1272-1273.
PubMed
P.396 掲載の参考文献
1) Graber JJ, et al. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 2009 ; 66 : 274-275.
PubMed
2) Matsuoka T, et al. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 2010 ; 120 : 651-660.
PubMed
3) Iannucci G, et al. Vanishing Balo-like lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000 ; 69 : 399-400.
PubMed
4) Kreft KL, et al. Spinal cord involvement in Balo's concentric sclerosis. J Neurol Sci 2009 ; 279 : 114-117.
PubMed
5) Karaarslan E, et al. Balo's concentric sclerosis : Clinical and radiologic features of five cases. AJNR Am J Neuroradiol 2001 ; 22 : 1362-1367.
PubMed

付録

P.402 掲載の参考文献
1) Polman CH, et al. Diagnostic criteria for multiple sclerosis : 2010 revisions to the "McDonald Criteria". Ann Neurol 2011 ; 69 : 292-302.
 
2) 藤原一男 (監訳). 多発性硬化症の診断基準- 2010年改訂McDonald基準. Ann Neurol日本語版 2011 ; 5 : 1-11.
 
3) Swanton JK, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006 ; 77 : 830-833.
PubMed
4) Swanton JK, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes : A multicentre retrospective study. Lancet Neurol 2007 ; 6 : 677-686.
PubMed
5) Montalban X, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010 ; 74 : 427-434.
PubMed

書評

最近チェックした商品履歴

Loading...